Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers
Status:
Recruiting
Trial end date:
2022-07-10
Target enrollment:
Participant gender:
Summary
A single dose, two-period trial where participants will be first given either of the 3
tocilizumab products on Day 1 during Period 1 and on Day 43/44/45 during Period 2
(flexibility for check-in for Period 2 given upto 3 days) either one of the remaining 2
tocilizumab products which the participant did not recieve earlier. Names of the 3
tocilizumab products are DRL_TC, RP and RMP. So if a participant receives DRL_TC on Day 1
Period 1 then he/she will either recieve RP/RMP on Day 43/44/45/46 during Period 2.